{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:31:13Z","timestamp":1790803873815,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T00:00:00Z","timestamp":1348790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T00:00:00Z","timestamp":1348790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00280-012-1977-9","type":"journal-article","created":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T08:56:03Z","timestamp":1348822563000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor\u2013positive metastatic breast cancer"],"prefix":"10.1007","volume":"71","author":[{"given":"Francisco J.","family":"Esteva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy L.","family":"Moulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Gonzalez-Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Ensor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie C.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly B.","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mong-Hong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Ching","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,28]]},"reference":[{"key":"1977_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.4161\/cc.8.6.7933","volume":"8","author":"IN Alimova","year":"2009","unstructured":"Alimova IN, Liu B, Fan Z et al (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8:909\u2013915","journal-title":"Cell Cycle"},{"key":"1977_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.exger.2005.07.007","volume":"40","author":"VN Anisimov","year":"2005","unstructured":"Anisimov VN, Berstein LM, Egormin PA et al (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2\/neu transgenic mice. Exp Gerontol 40:685\u2013693","journal-title":"Exp Gerontol"},{"key":"1977_CR3","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/S0140-6736(09)60316-0","volume":"373","author":"JR Benson","year":"2009","unstructured":"Benson JR, Jatoi I, Keisch M et al (2009) Early breast cancer. Lancet 373:1463\u20131479","journal-title":"Lancet"},{"key":"1977_CR4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/jnci\/djn233","volume":"100","author":"AM Brewster","year":"2008","unstructured":"Brewster AM, Hortobagyi GN, Broglio KR et al (2008) Residual risk of breast cancer recurrence 5\u00a0years after adjuvant therapy. J Natl Cancer Inst 100:1179\u20131183","journal-title":"J Natl Cancer Inst"},{"key":"1977_CR5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/jms.1566","volume":"44","author":"G Corona","year":"2009","unstructured":"Corona G, Elia C, Casetta B et al (2009) A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma. J Mass Spectrom 44:920\u2013928","journal-title":"J Mass Spectrom"},{"key":"1977_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1200\/JCO.2007.13.3744","volume":"26","author":"LY Dirix","year":"2008","unstructured":"Dirix LY, Ignacio J, Nag S et al (2008) Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 26:1253\u20131259","journal-title":"J Clin Oncol"},{"key":"1977_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/A:1016114026769","volume":"74","author":"E Elstner","year":"2002","unstructured":"Elstner E, Williamson EA, Zang C et al (2002) Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 74:155\u2013165","journal-title":"Breast Cancer Res Treat"},{"key":"1977_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.9-suppl_3-4","volume":"9","author":"FJ Esteva","year":"2004","unstructured":"Esteva FJ (2004) Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 9:4\u20139","journal-title":"Oncologist"},{"key":"1977_CR9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1200\/JCO.2003.05.068","volume":"21","author":"FJ Esteva","year":"2003","unstructured":"Esteva FJ, Glaspy J, Baidas S et al (2003) Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 21:999\u20131006","journal-title":"J Clin Oncol"},{"key":"1977_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0889-8588(05)70065-4","volume":"13","author":"FJ Esteva","year":"1999","unstructured":"Esteva FJ, Hortobagyi GN (1999) Locally advanced breast cancer. Hematol Oncol Clin North Am 13:457\u2013472","journal-title":"Hematol Oncol Clin North Am"},{"key":"1977_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/bcr777","volume":"6","author":"FJ Esteva","year":"2004","unstructured":"Esteva FJ, Hortobagyi GN (2004) Prognostic molecular markers in early breast cancer. Breast Cancer Res 6:109\u2013118","journal-title":"Breast Cancer Res"},{"key":"1977_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.breast.2005.08.033","volume":"15","author":"FJ Esteva","year":"2006","unstructured":"Esteva FJ, Hortobagyi GN (2006) Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 15:301\u2013312","journal-title":"Breast"},{"key":"1977_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1053\/srao.2002.35251","volume":"12","author":"FJ Esteva","year":"2002","unstructured":"Esteva FJ, Sahin AA, Cristofanilli M et al (2002) Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 12:319\u2013328","journal-title":"Semin Radiat Oncol"},{"key":"1977_CR14","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1001\/jama.283.13.1695","volume":"283","author":"V Fonseca","year":"2000","unstructured":"Fonseca V, Rosenstock J, Patwardhan R et al (2000) Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283:1695\u20131702","journal-title":"JAMA"},{"key":"1977_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1385\/ENDO:26:1:019","volume":"26","author":"C Han","year":"2005","unstructured":"Han C, Zhang HT, Du L et al (2005) Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine 26:19\u201324","journal-title":"Endocrine"},{"key":"1977_CR16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/BD-2003-17104","volume":"17","author":"SE Hankinson","year":"2003","unstructured":"Hankinson SE, Schernhammer ES (2003) Insulin-like growth factor and breast cancer risk: evidence from observational studies. Breast Dis 17:27\u201340","journal-title":"Breast Dis"},{"key":"1977_CR17","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1158\/1078-0432.CCR-05-0915","volume":"11","author":"PR Hutson","year":"2005","unstructured":"Hutson PR, Love RR, Havighurst TC et al (2005) Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Clin Cancer Res 11:8722\u20138727","journal-title":"Clin Cancer Res"},{"key":"1977_CR18","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1200\/JCO.2006.06.5599","volume":"24","author":"CC Jaffe","year":"2006","unstructured":"Jaffe CC (2006) Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:3245\u20133251","journal-title":"J Clin Oncol"},{"key":"1977_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10911-008-9107-3","volume":"13","author":"Q Jin","year":"2008","unstructured":"Jin Q, Esteva FJ (2008) Cross-talk between the ErbB\/HER family and the type i insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13:485\u2013498","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"1977_CR20","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","volume":"27","author":"S Jiralerspong","year":"2009","unstructured":"Jiralerspong S, Palla SL, Giordano SH et al (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297\u20133302","journal-title":"J Clin Oncol"},{"key":"1977_CR21","first-page":"1101","volume":"3","author":"DC Johannessen","year":"1997","unstructured":"Johannessen DC, Engan T, Di Salle E et al (1997) Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3:1101\u20131108","journal-title":"Clin Cancer Res"},{"key":"1977_CR22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1124\/dmd.110.032276","volume":"39","author":"LK Kamdem","year":"2011","unstructured":"Kamdem LK, Flockhart DA, Desta Z (2011) In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 39:98\u2013105","journal-title":"Drug Metab Dispos"},{"key":"1977_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1470-2045(00)00254-0","volume":"2","author":"TJ Key","year":"2001","unstructured":"Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2:133\u2013140","journal-title":"Lancet Oncol"},{"key":"1977_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1023\/B:CACO.0000024225.14618.a8","volume":"15","author":"DA Lawlor","year":"2004","unstructured":"Lawlor DA, Smith GD, Ebrahim S (2004) Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women\u2019s Heart and Health Study. Cancer Causes Control 15:267\u2013275","journal-title":"Cancer Causes Control"},{"key":"1977_CR25","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1634\/theoncologist.2008-0112","volume":"13","author":"DJ Lenihan","year":"2008","unstructured":"Lenihan DJ, Esteva FJ (2008) Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist 13:1224\u20131234","journal-title":"Oncologist"},{"key":"1977_CR26","doi-asserted-by":"crossref","first-page":"6S88","DOI":"10.1016\/S1262-3636(03)72792-X","volume":"29","author":"XM Leverve","year":"2003","unstructured":"Leverve XM, Guigas B, Detaille D et al. (2003) Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 29:6S88\u20136S94","journal-title":"Diabetes Metab"},{"key":"1977_CR27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nm.2332","volume":"17","author":"M Lu","year":"2011","unstructured":"Lu M, Sarruf DA, Talukdar S et al (2011) Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 17:618\u2013622","journal-title":"Nat Med"},{"key":"1977_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1530\/eje.1.02331","volume":"156","author":"A Majuri","year":"2007","unstructured":"Majuri A, Santaniemi M, Rautio K et al (2007) Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 156:263\u2013269","journal-title":"Eur J Endocrinol"},{"key":"1977_CR29","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1210\/jc.2003-031279","volume":"88","author":"N Mauras","year":"2003","unstructured":"Mauras N, Lima J, Patel D et al (2003) Pharmacokinetics and dose finding of a potent aromatase inhibitor, Aromasin (exemestane), in young males. J Clin Endocrinol Metab 88:5951\u20135956","journal-title":"J Clin Endocrinol Metab"},{"key":"1977_CR30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1940-6207.CAPR-11-0110","volume":"4","author":"PG Morris","year":"2011","unstructured":"Morris PG, Hudis CA, Giri D et al (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 4:1021\u20131029","journal-title":"Cancer Prev Res (Phila)"},{"key":"1977_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.8-1-5","volume":"8","author":"R Nahta","year":"2003","unstructured":"Nahta R, Hortobagyi GN, Esteva FJ (2003) Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8:5\u201317","journal-title":"Oncologist"},{"key":"1977_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2125.2004.02161.x","volume":"58","author":"JY Park","year":"2004","unstructured":"Park JY, Kim KA, Shin JG et al (2004) Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol 58:397\u2013402","journal-title":"Br J Clin Pharmacol"},{"key":"1977_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1015288615472","volume":"13","author":"JM Petrelli","year":"2002","unstructured":"Petrelli JM, Calle EE, Rodriguez C et al (2002) Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 13:325\u2013332","journal-title":"Cancer Causes Control"},{"key":"1977_CR34","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1200\/JCO.2001.19.6.1716","volume":"19","author":"E Rivera","year":"2001","unstructured":"Rivera E, Valero V, Syrewicz L et al (2001) Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19:1716\u20131722","journal-title":"J Clin Oncol"},{"key":"1977_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1467-789X.2004.00142.x","volume":"5","author":"DP Rose","year":"2004","unstructured":"Rose DP, Komninou D, Stephenson GD (2004) Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5:153\u2013165","journal-title":"Obes Rev"},{"key":"1977_CR36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/cpt1978246683","volume":"24","author":"CR Sirtori","year":"1978","unstructured":"Sirtori CR, Franceschini G, Galli-Kienle M et al (1978) Disposition of metformin (N, N-dimethylbiguanide) in man. Clin Pharmacol Ther 24:683\u2013693","journal-title":"Clin Pharmacol Ther"},{"key":"1977_CR37","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","volume":"54","author":"CM Sturgeon","year":"2008","unstructured":"Sturgeon CM, Duffy MJ, Stenman UH et al (2008) National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54:e11\u2013e79","journal-title":"Clin Chem"},{"key":"1977_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1677\/ERC-06-0089","volume":"14","author":"YF Tian","year":"2007","unstructured":"Tian YF, Chu CH, Wu MH et al (2007) Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer 14:669\u2013677","journal-title":"Endocr Relat Cancer"},{"key":"1977_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10549-007-9787-1","volume":"111","author":"TA Traina","year":"2008","unstructured":"Traina TA, Poggesi I, Robson M et al (2008) Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat 111:377\u2013388","journal-title":"Breast Cancer Res Treat"},{"key":"1977_CR40","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1056\/NEJMra050776","volume":"354","author":"JD Yager","year":"2006","unstructured":"Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270\u2013282","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1977-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-012-1977-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1977-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1977-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:41:23Z","timestamp":1659058883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-012-1977-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,28]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["1977"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1977-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,28]]},"assertion":[{"value":"27 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}